IPC분류정보
| 국가/구분 |
United States(US) Patent
등록
|
| 국제특허분류(IPC7판) |
|
| 출원번호 |
UP-0451516
(2006-06-12)
|
| 등록번호 |
US-7790673
(2010-09-27)
|
|
발명자
/ 주소 |
|
| 출원인 / 주소 |
|
| 대리인 / 주소 |
|
| 인용정보 |
피인용 횟수 :
1 인용 특허 :
38 |
초록
▼
A method of treating amyloidoses by administering an effective amount of a cystatin C composition. A method of preventing and inhibiting Aβ oligomerization by administering an effective amount of a cystatin C composition. A composition for inhibiting Aβ oligomerization including an effec
A method of treating amyloidoses by administering an effective amount of a cystatin C composition. A method of preventing and inhibiting Aβ oligomerization by administering an effective amount of a cystatin C composition. A composition for inhibiting Aβ oligomerization including an effective amount of a cystatin C composition. A method of diagnosing disease by assaying for a biomarker comprising a cystatin C complex. A biomarker for disease including a cystatin C complex.
대표청구항
▼
What is claimed is: 1. A method of treating amyloidoses in a patient in need of treatment thereof, said method comprising administering an effective amount of a cystatin C, wherein the cystatin C has the ability to bind amyloid β(A β) and is chosen from the group consisting of a natural
What is claimed is: 1. A method of treating amyloidoses in a patient in need of treatment thereof, said method comprising administering an effective amount of a cystatin C, wherein the cystatin C has the ability to bind amyloid β(A β) and is chosen from the group consisting of a natural cystatin C peptide, a synthetic cystatin C peptide, fragments thereof, moieties thereof, and combinations thereof, and thereby treating amyloidoses. 2. The method according to claim 1, wherein said administering step is further defined as local administering of an effective amount of the cystatin C. 3. The method according to claim 1, wherein said administering step is further defined as systemic administering of an effective amount of the cystatin C. 4. The method according to claim 1, wherein the amyloidoses are selected from the group consisting of Alzheimer's disease, Down syndrome, hereditary cerebral hemorrhage with amyloidosis—Dutch type (HCHWA-D, familial British dementia (FBD), familial Danish dementia (FDD), Gerstmann-Str&ussler -Scheinker disease (GSS), Creutzfeldt-Jakob disease (CJD), and prion diseases. 5. A method of inhibiting A βoligomerization in a patient in need of treatment thereof, said method comprising administering an effective amount of a cystatin C chosen from the group consisting of a natural cystatin C peptide, a synthetic cystatin C peptide, fragments thereof, moieties thereof, and combinations thereof, and thereby inhibiting Aβoligomerization. 6. The method according to claim 5, wherein said administering step is further defined as locally administering an effective amount of the cystatin C. 7. The method according to claim 5, wherein said administering step is further defined as systemically administering an effective amount of the cystatin C. 8. The method according to claim 5, wherein the oligomerization is caused by a disease selected from the group consisting of Alzheimer's disease, Down syndrome, hereditary cerebral hemorrhage with Amyloidosis—Dutch type (HCHWA-D, familial British dementia (FBD), familial Danish dementia (FDD), Gerstmann-Str&ussler-Scheinker disease (GSS), Creutzfeldt-Jakob disease (CJD), and prion diseases. 9. A method of inhibiting fibril formation or deposition in a patient in need of treatment thereof, said method comprising administering an effective amount of a cystatin C , wherein the cystatin C has the ability to bind amyloid β(A β) and is chosen from the group consisting of a natural cystatin C peptide, a synthetic cystatin C peptide, fragments thereof, moieties thereof, and combinations thereof, and thereby inhibiting fibril formation or deposition.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.